Altimmune (NASDAQ:ALT) Announces Earnings Results, Beats Expectations By $0.02 EPS

Altimmune (NASDAQ:ALT) released its quarterly earnings data on Tuesday. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02, FiscalAI reports. Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 42.57%.

Altimmune Trading Down 2.3%

Shares of NASDAQ ALT opened at $2.93 on Thursday. Altimmune has a 1-year low of $2.56 and a 1-year high of $6.44. The business has a fifty day moving average price of $2.90 and a 200 day moving average price of $3.42. The stock has a market capitalization of $569.80 million, a P/E ratio of -3.15 and a beta of 0.27. The company has a debt-to-equity ratio of 0.12, a current ratio of 29.56 and a quick ratio of 29.56.

Hedge Funds Weigh In On Altimmune

Large investors have recently added to or reduced their stakes in the company. Northeast Financial Group Inc. acquired a new stake in Altimmune in the 4th quarter worth approximately $48,000. &PARTNERS purchased a new position in Altimmune in the 4th quarter worth $54,000. Vontobel Holding Ltd. acquired a new stake in Altimmune during the 4th quarter worth about $54,000. Martingale Asset Management L P acquired a new stake in Altimmune during the 4th quarter worth about $52,000. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Altimmune during the 4th quarter valued at about $44,000. 78.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ALT shares. Citigroup reaffirmed a “market outperform” rating on shares of Altimmune in a research note on Tuesday, June 2nd. Citizens Jmp dropped their target price on shares of Altimmune from $14.00 to $11.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating on shares of Altimmune in a research report on Tuesday, July 28th. Wall Street Zen upgraded shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Leerink Partners started coverage on shares of Altimmune in a research report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $14.33.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.